CSCI.TO COSCIENS Biopharma Inc.
- Market cap
- CAD 8.48M
- P/E
- -
- P/B
- 0.40x
- ROE
- -9.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CSCI.TO undervalued?
Graham numberThe Graham number of COSCIENS Biopharma Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
COSCIENS Biopharma Inc. fundamental analysis
No fundamental analysis for COSCIENS Biopharma Inc. yet.
COSCIENS Biopharma Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from …
Full company profileCOSCIENS Biopharma Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
COSCIENS Biopharma Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 911K | 923K | 26.9M | 532K | 3.65M | 5.26M | 14.6M | 4.50M | 9.59M | 7.63M | 9.84M |
| Gross Profit | 911K | 923K | 24.8M | 122K | 1.34M | 5.17M | 8.56M | 4.28M | 4.73M | 2.69M | 4.94M |
| Operating Income | -29.5M | -23.1M | 9.84M | -9.71M | -5.93M | -8.67M | -15.4M | -18.0M | -14.0M | -10.6M | -614K |
| EBITDA | -29.3M | -22.9M | 9.90M | -9.40M | -6.11M | 2.85M | -13.9M | -16.6M | -13.5M | -9.41M | 714K |
| Net Income | -25.0M | -16.8M | 4.19M | -6.04M | 1.46M | 2.64M | 3.24M | -3.55M | -15.3M | -10.5M | -1.45M |
| EPS | -527 | -253 | 55 | -78 | 7.97 | 5.17 | 6.01 | -6.58 | -18 | -30 | -1.38 |
| Balance Sheet | |||||||||||
| Total Assets | 31.7M | 22.2M | 25.0M | 20.0M | 37.3M | 80.1M | 56.0M | 37.0M | 35.1M | 21.4M | 18.8M |
| Total Liabilities | 25.4M | 25.0M | 23.1M | 22.4M | 24.1M | 27.1M | 20.3M | 18.8M | 21.9M | 17.6M | 4.00M |
| Shareholders' Equity | 6.21M | -2.78M | 1.91M | -2.46M | 13.2M | 53.0M | 35.8M | 18.2M | 13.2M | 3.84M | 14.8M |
| Cash & Short-term Investments | 22.0M | 7.78M | 14.5M | 7.84M | 24.3M | 65.3M | 50.6M | 34.0M | 16.4M | 7.29M | 5.27M |
| Total Debt | - | - | 738K | 903K | 2.38M | 4.16M | 3.86M | 3.39M | 2.31M | 2.15M | 1.95M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -29.0M | -22.9M | 6.83M | -10.7M | -4.13M | -8.58M | -13.7M | -17.1M | -14.6M | -8.62M | -3.14M |
| Capital Expenditure | 66.0K | 4.00K | 9.00K | 3.76 | 619K | 639K | 11.0K | 19.0K | 1.16M | 718K | 19.5K |
| Free Cash Flow | -29.1M | -22.9M | 6.82M | -10.7M | -4.75M | -9.22M | -13.7M | -17.1M | -15.7M | -9.34M | -3.16M |
| Ratios | |||||||||||
| ROE | -401.8% | - | 219.6% | - | 11.0% | 5.0% | 9.1% | -19.5% | -116.3% | -274.8% | -9.8% |
| ROA | -78.8% | -75.7% | 16.7% | -30.2% | 3.9% | 3.3% | 5.8% | -9.6% | -43.7% | -49.3% | -7.7% |
| Net Profit Margin | -2,739.7% | -1,819.7% | 15.6% | -1,135.7% | 39.9% | 50.2% | 22.2% | -78.9% | -159.7% | -138.1% | -14.7% |
| Debt to Equity | - | - | 0.39x | - | 0.18x | 0.08x | 0.11x | 0.19x | 0.18x | 0.56x | 0.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
COSCIENS Biopharma Inc. dividends
COSCIENS Biopharma Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 50:150 on Jul 7, 2026.
Who owns COSCIENS Biopharma Inc.
- Insiders 27.53%
- Institutions 0.00%
- Public & others 72.47%
- Shares outstanding 997K
- Free float 991K
COSCIENS Biopharma Inc. company profile
- Company name
- COSCIENS Biopharma Inc.
- Ticker
- CSCI.TO
- ISIN
- CA22112H1010
- Exchange
- Toronto Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 28
- Fiscal year end
- December
- Address
- 22 Adelaide Street West, Toronto, ON, Canada, M5H 4E3
- Phone
- 843 900 3223
- Website
- cosciensbio.com
About COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. In addition, it focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
COSCIENS Biopharma Inc. management
3- Mr. Peter Harry Puccetti CFACEO, President & Chairman
- Mr. Giuliano La FrattaSenior VP of Finance & CFO
- Mr. Michel Regnier P. Eng.Senior VP & MD of Edmonton